key: cord-0757387-oqfl2f5k
authors: Lim, Ming Sheng; Mcrae, Simon
title: COVID-19 and Immunothrombosis: Pathophysiology and therapeutic implications
date: 2021-11-17
journal: Crit Rev Oncol Hematol
DOI: 10.1016/j.critrevonc.2021.103529
sha: dfa09d98696c82be9e82d6425f3020f42aad9df5
doc_id: 757387
cord_uid: oqfl2f5k

The coagulopathy of COVID-19 is characterised by significantly elevated D Dimer and fibrinogen, mild thrombocytopenia and a mildly prolonged PT/APTT. A high incidence of thrombotic complications occurs despite standard thromboprophylaxis. The evidence to date supports immunothrombosis as the underlying mechanism for this coagulopathy which is triggered by a hyperinflammatory response and endotheliopathy. A hypercoagulable state results from endothelial damage/activation, complement activation, platelet hyperactivity, release of Extracellular Neutrophil Traps, activation of the coagulation system and a “hypofibrinolytic” state. Significant cross-talk occurs between the innate/adaptive immune system, endothelium and the coagulation system. D dimer has been shown to be the most reliable predictor of disease severity, thrombosis, and overall survival. In this context, targeting pathways upstream of coagulation using novel or repurposed drugs alone or in combination with other anti-thrombotic agents may be a rational approach to prevent the mortality/morbidity due to COVID-19 associated coagulopathy.

the Australian Haemophilia Centre Director's organization, and currently is the chair of the steering committee of the Australian Bleeding Disorder Registry.

Word Count: 143 (Abstract) 5099 (text)

The emergence of coronavirus 2019 (COVID-19), a new disease entity caused by the severe acute respiratory syndrome coronavirus 2 (SARS-COV2) virus has led to an unprecedented global health crisis. It was first declared a global pandemic by the World Health Organisation on 11 March 2020 and as of 10 September 2021, over 223 million cases have been reported worldwide, with 4.6 million deaths attributed to this devastating disease. The clinical spectrum ranges from asymptomatic carriers to a critical illness manifested by acute respiratory distress syndrome which occurs in about 5% of patients typically around day 10 of the onset of illness and can progress to respiratory failure, multiorgan failure and death [1] . While the reasons that predispose some individuals to a more severe illness are poorly understood, severe disease has been associated with a hypercoagulable state.

Indeed, the coagulopathy associated with COVID-19 characterized by elevated D-dimer and fibrin degradation products (FDPs) has been shown to correlate with disease severity and increased mortality [2] . In addition, COVID-19 is associated with an increased rate of thrombotic complications J o u r n a l P r e -p r o o f including microvascular, venous thromboembolism and arterial thrombosis [3] . Further, the incidence of thrombotic complications associated with COVID-19 appears to be higher in intensive care unit (ICU) patients with COVID-19 than Non-COVID-19 ICU patients and other respiratory viruses such as Middle East respiratory syndrome (MERS) coronavirus and influenza viruses [4] . Various mechanisms have been proposed to explain the coagulopathy caused by COVID-19, although immunothrombosis, an interplay between the immune system and the coagulation pathway is believed to be the primary underlying mechanism. In this narrative review we discuss the pathophysiology, clinical, laboratory and therapeutic implications of COVID-19 coagulopathy. A summary of the pathophysiology is shown in Figure 1 .

SARS-Cov-2 enters the host cell by binding to the transmembrane Angiotensin Converting Enzyme 2 (ACE2) receptor via the S1 subunit of its spike protein. This receptor is widely expressed in a variety of cell types and organs throughout the body including the lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue. In addition to ACE2, SARS-COV-2 also binds to heparan sulphate, a cell surface glycosaminoglycan via the receptor binding domain on S1 which induces a conformational change in of S1, thus enhancing its interaction with ACE2 [5] . Fusion of the S2 subunit with the host membrane is facilitated by a serine protease, Transmembrane protease serine 2 (TMPRSS2) which primes this step by proteolytic cleavage of the S2 binding site. Binding of SARs-COV-2 to ACE2 leads to subsequent downregulation of surface ACE2 expression which may be mediated by proteolysis and ectodomain shedding of ACE-2 by A Disintegrin And Metalloproteinase-17 (ADAM-17). [6] . ACE-2 is an important mediator of the Renin-Angiotensin System, converting Angiotensin 2 to Angiotensin 1-7. Angiotensin 2 is a potent vasoconstrictor which has pro-inflammatory and profibrotic effects while Angiotensin 1-7 is a vasodilator which negatively regulates the Renin Angiotensin J o u r n a l P r e -p r o o f system and has cardioprotective effects. Downregulation of ACE-2 therefore leads to unopposed angiotensin II effects, including proinflammatory, prothrombotic, and pro-oxidant risks. In addition, differences in tissue expression of ACE-2 receptor and activating proteases may contribute to unique aspects of the pathophysiology of different coronaviruses.

Severe COVID-19, is characterised by a hyperinflammatory response with elevated levels of ferritin, CRP, and cytokines such as interleukin-2R (IL-2R), IL-6, IL-8, IL-10, and Tumour Necrosis Factor alpha (TNF-α) [7, 8] . In particular, IL-6 has been shown to be selectively induced by SARS-CoV-2 and circulating IL-6 levels are closely associated with the severity of COVID-19 [9] . The release of proinflammatory cytokines is believed to be triggered by pathogen-associated molecular patterns (PAMPs) and host derived damage-associated molecular patterns (DAMPs) leading to activation of the immune system [10] of which macrophages and monocytes are believed to play a key role [11] . This is supported by the detection of macrophage/monocyte attracting chemokines such as monocyte chemotactic protein 1 (MCP-1), interferon-inducible protein-10, macrophage inflammatory protein-1α in the Bronchial Alveolar Lavage Fluid (BALF) obtained from COVID-19 patients [12] and similarities in the cytokine profile of patients with severe COVID-19 pneumonia and other hyperinflammatory syndromes such as macrophage activation syndrome or secondary haemophagocytosis lymphohistiocytosis [13, 14] .

In children, a delayed hyperinflammatory syndrome has also been recognised which typically occurs 2-6 weeks after SARS-CoV-2 infection. This rare but serious condition has been termed multisystem inflammatory syndrome in children associated with COVID-19 (MIS-C) or paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) although it has also been reported in adolescents [15] . It shares similar clinical features with Kawasaki disease, but affects older children and more often presents with intestinal involvement, myocardial failure and shock [16] .

Although the hyperinflammatory response has been referred widely in the literature as "cytokine storm syndrome", use of this term in COVID-19 is controversial. Critics have argued that to date there has been no standard definition for the "cytokine storm syndrome" and that compared to non-COVID-19 acute respiratory distress syndrome (ARDS), levels of IL-6 and other cytokines in severe COVID-19 patients are significantly lower (typically 10-200 fold) [17, 18] . Further, distinguishing an appropriate from a dysregulated inflammatory response in the pathophysiology of critical illness is challenging and this has implications for the use of anti-cytokine therapies such as IL-6 inhibitors and high dose corticosteroids which may block pathways critical to host immune response. This has led to the proposal to use the alternative term "systemic inflammatory response syndrome" which has historically been described in patients with sepsis [17] .

While severe COVID-19 is associated with an excessive inflammatory response, it should be noted that immunosuppression or immune-paralysis occurs concurrently in patients with severe COVID-19.

This manifests as progressive lymphopenia, with a decrease in lymphocytes, predominantly CD4+ and CD8+ T cells, resulting in a decrease in numbers as well as IFN-γ production by CD4+ T cells which may correlate with disease severity [8, 19, 20 ].

An association between hyperinflammation characterised by elevated cytokine levels and coagulopathy is supported by work by Ranucci et al. who demonstrated a correlation between IL-6 and fibrinogen levels in patients with COVID-19 acute respiratory distress syndrome [21] . A few mechanisms have been postulated to explain how this hyperinflammatory response leads to thrombosis [22] which include: (1) increased expression of tissue factor (TF) on monocytes/macrophages and vascular endothelial cells stimulated by pro-inflammatory cytokines such as Tumour necrosis factor-α, IL-1β, IL-6 thus promoting coagulation via the extrinsic pathway [23] (2) suppression of the fibrinolytic system by decreased activity of urokinase-type plasminogen activator and increased release of plasminogen activator inhibitor-1 (3) platelet activation by various proinflammatory cytokines and (4) endothelial damage by the inflammatory reaction. Conversely, J o u r n a l P r e -p r o o f thrombin generation enhances the release of pro-inflammatory cytokines such as IL-6 and TNF-a by monocytes through protease-activated receptors (PARs). Thus there is significant cross-talk between inflammation and coagulation which leads to a vicious cycle. [24] .

The intact endothelium plays an important role in maintaining haemostasis under physiological conditions by providing a protective glycocalyx barrier to the thrombogenic subendothelial basement membrane, as well as regulating tight junctions, adhesion molecules and vascular tone. It also has antithrombotic properties through the expression of antiplatelet (e.g. nitric oxide and prostacyclin) and anticoagulant (e.g. antithrombin, thrombomodulin, Endothelial protein C receptor (EPCR), and heparin-like proteoglycans) mediators [25] . SARs-Cov-2 infection results in endothelial damage/activation which can be mediated via direct or indirect mechanisms. Evidence for direct viral infection of the endothelial cell is supported by a study by Varga et al. [26] who showed that direct viral infection was associated with diffuse endothelial inflammation and apoptosis. Several mechanisms for this have been described of which activation of the NLR family pyrin domain containing 3 (NLRP3) inflammasome [27] , leading to pyroptosis, an inflammatory form of programmed cell death usually seen in infections by intracellular pathogens is believed to play a major role [28, 29] .

The endothelium can also be activated by indirect mechanisms including pro-inflammatory cytokines, downregulation of ACE2, hypoxia, complement activation, and Neutrophil Extracellular Traps (NET)osis [30] . This in turn leads to activation of the coagulation system through a number of mechanisms [31] such as (1) exposure of the thrombogenic basement membrane (2) release of factor VIII (FVIII), von Willebrand factor (VWF) and P-selectin from Weibel-Palade bodies (WPB) and (3) release of Vascular Endothelial Growth factor (VEGF), from activated platelets which causes upregulated expression of TF.

Evidence for endothelial activation/dysfunction leading to coagulopathy is supported by biomarker and postmortem studies in COVID-19 patients. Goshua et al. showed that markers of endothelial cell J o u r n a l P r e -p r o o f activation, including VWF antigen/antibody, FVIII activity, and thrombin antithrombin (TAT) complexes were significantly higher in intensive care unit (ICU) patients with severe COVID-19 compared to non-ICU patients [32] . In addition, a post-mortem study by Ackermann et al. demonstrated that alveolar capillary microthrombi were nine times as prevalent in patients who died from respiratory failure caused by SARS-CoV-2 infection as in patients with influenza, thus supporting the hypothesis of endothelial injury-mediated microvascular thrombosis in COVID-19 [33] .

While platelets have an established role in haemostasis and thrombosis, their role in the immune response to pathogens is also increasingly being recognised [34] . Thrombocytopenia occurs in 5-40% of patients with COVID-19 [35] and is associated with severe disease and increased mortality. [36] Recent studies have also demonstrated that COVID-19 is associated with platelet hyperreactivity, [37] [38] [39] thus suggesting that platelets may contribute to COVID 19 coagulopathy. Unlike sepsis induced coagulopathy/disseminated intravascular coagulopathy (SIC/DIC) however, the coagulopathy associated with COVID-19 is characterized by significantly elevated D Dimer levels and fibrinogen and only mild thrombocytopenia. The exact mechanisms for how platelets may contribute to coagulopathy in COVID-19 have yet to be elucidated although several possible mechanisms have been discussed in recent reviews [3, 40] . One leading hypothesis is internalisation of the SARs-CoV2 virus by platelets which has been previously described in studies of patients infected with influenza, a single stranded RNA virus similar to SARs-CoV-2. This leads to activation of the Toll-like receptor TLR-7 resulting in the release of complement C3 from platelet alpha granules which in turn stimulates the release of NETs, a scaffold and potent activator of coagulation via multiple mechanisms. While there is ongoing debate as to whether internalisation of SARS-CoV-2 by platelets occurs and whether ACE2 the main receptor for SARS-CoV2 is expressed on platelets, platelets can also be activated by other mechanisms such as the release of tissue factor, platelet activating factor (PAF) and binding of platelet GP (Glycoprotein) VI to collagen. Coagulation is subsequently triggered by platelet degranulation and aggregation, J o u r n a l P r e -p r o o f chemokine induced leucocyte-platelet aggregates, as well as release of platelet derived inorganic polyphosphate and tissue bearing microvesicles.

As a first-line host defence against foreign microbes, neutrophils release NETs, web-like structures composed of Deoxyribonucleic acid (DNA) filaments coated with histones and granule proteins.

However, in addition to its immune function, NETs also provide a scaffold for platelet, red blood cells, TF bearing extracellular vesicles and pro-coagulant molecules (e.g. VWF, fibronectin, fibrinogen, FXII, and TF), thus leading to activation of platelets and the coagulation system. The pro-coagulant effect of NETs is perpetuated by cross-talk between the endothelium, platelets and neutrophils/NETs resulting in a vicious circle which leads to further thrombus formation [41] . Of note, studies on respiratory viral infections have demonstrated a key role for neutrophils in clearing viruses in the lung by phagocytosing viral particles and by releasing NETs [42, 43] . In keeping with this, high levels of markers of NETs (cell-free DNA, myeloperoxidase-DNA complexes, and citrullinated histone H3) are found in the plasma of patients with COVID-19 which have been shown to corelate with disease severity [44] [45] [46] . Further, in lung tissue obtained from autopsies of COVID-19 patients, NETs were associated with microthrombi and platelet deposition [44, 45, 47] . Interestingly, NETosis can be induced by plasma from COVID-19 patients [44, 47] which can be successfully blocked by a NETinhibitory peptide [44] . In clinical studies, markers of NETs were associated with higher risk of morbid thrombotic events despite prophylactic anticoagulation in hospitalised COVID-19 patients [48] . Taken together, this suggests that NETosis plays an important role in COVID-19 associated coagulopathy/thrombosis.

The complement system is a key mediator of the innate immune response that can be activated by three pathways (classical, lectin, and alternative) of which binding of the lectin pathway of complement component mannan-binding lectin (MBL) via the SARS CoV-1 spike protein is believed to J o u r n a l P r e -p r o o f be the likely mechanism of systemic activation of complement in COVID-19 [49] . C3a and C5a anaphylatoxins recruit and/or activate neutrophils, monocytes, endothelial cells and platelets resulting in the release of proinflammatory cytokines which promotes coagulation as previously described. Significant interaction occurs between the complement and coagulation systems. C5a upregulates TF expression on neutrophils and endothelial cells and stimulates secretion of VWF from endothelial cells. In addition, C5a also impairs fibrinolysis by increasing the release of plasminogen activator inhibitor 1 (PAI-1) from mast cells and basophils [50] . Coagulation factors FXa, FXIa and plasmin in turn cleave both C5 and C3, to generate C5a and C3a while thrombin cleaves C5 to generate C5a [51] . The complement system is also activated by Contact pathway factors, such as FXIIa which activates complement C1, leading to activation of the classical pathway of complement [52] , and kallikrein which cleaves both C3 and factor B [53] . In addition, indirect activation of coagulation by the complement system occurs via C5a induced NETosis while neutrophils themselves can activate the complement system. Finally, there is also reciprocal activation between platelets and the complement system [54] .

Excessive complement activation leading to widespread microvascular thrombosis is known to occur in a number of pathological settings. The classic example is atypical haemolytic-uremic syndrome (aHUS), a rare disorder of uncontrolled complement activation characterized by microangiopathic haemolytic anaemia, thrombocytopenia, and acute renal failure. [55] . Evidence that the complement system may play a role in the coagulopathy of COVID-19 in at least a subset of patients was demonstrated in a case series of 5 patients with severe COVID-19. Autopsies of these patients showed evidence of deposition of C5b-9 (membrane attack complex), C4d, and mannose binding lectin (MBL)associated serine protease (MASP)2 in the microvasculature of their lungs and skin. In addition, two of these patients also had co-localization of COVID-19 spike glycoproteins with C4d and C5b-9 in the interalveolar septa and the cutaneous microvasculature [56] . In this context, studies of complement inhibition in murine models of SARS-CoV and MERS-CoV, coronaviruses similar to SARS-COV-2, have demonstrated improved outcomes [49, 57] suggesting a role for complement inhibitors in COVID-19.

J o u r n a l P r e -p r o o f

Antiphospholipid syndrome is an acquired thrombophilia characterised by thrombotic events or pregnancy morbidity and the presence of persistently positive antiphospholipid antibodies. Evidence for an association between antiphospholipid antibodies and COVID-19 coagulopathy/thrombosis emerged from an early report of three COVID-19 ICU patients with multiple cerebral infarcts who tested positive for IgA anticardiolipin antibodies and IgA/G anti-Beta 2-glcoprotein antibodies [58] .

This was followed by reports of a high incidence of positive Lupus anticoagulant (45-87%) among non-ICU and ICU patients with COVID-19 [59, 60] . Subsequently, the presence of antiphospholipid antibodies and/or lupus anticoagulant in COVID-19 patients was confirmed in other studies [61] [62] [63] [64] with one study demonstrating a correlation between IgG anticardiolipin antibodies and severity of disease [64] . This has been tempered by counter-arguments that antiphospholipid antibodies often appear transiently during critical illness and infections, the use of heparin and marked elevation of C-Reactive Protein (CRP) in most of these patients which can cause false positive lupus anticoagulant tests, the inclusion of non-criteria antiphospholipid antibodies and the baseline high incidence of thrombosis in the patient populations studied [65] . Indeed, several subsequent studies have shown that the detection of lupus anticoagulant was not associated with an increased risk of thrombosis. In addition, cases of triple positive antibodies were rare, and the antibodies were transient in most cases (negative on repeat testing) [66] [67] [68] suggesting that antiphospholipid antibodies are an epiphenomenon rather than pathogenic in COVID-19 coagulopathy. Interestingly, however, a recent Further studies are therefore required to clarify the presence, temporal association and role of antiphospholipid antibodies in COVID-19 patients.

J o u r n a l P r e -p r o o f

Suppressed fibrinolysis due to elevated levels of PAI-1 has been described in acute lung injury and SIC/DIC [70, 71] . This has led to the suggestion that abnormalities in the fibrinolytic system may play an important role in acute lung injury caused by COVID-19 associated coagulopathy. Indeed, in a mouse model of acute lung injury by SARS-CoV infection, levels of Serpine1, a urokinase inhibitor were elevated, while Serpine1 knockout mice demonstrated increased fibrinolytic activity and haemorrhage in the lungs thus highlighting the role of the urokinase pathway in the pathogenesis of SARS-CoV induced acute lung injury [72] . In humans, impaired fibrinolysis has also been reported in SARS-CoV2 infected patients which was mainly associated with high PAI-1 levels [73] . In addition, fibrinolysis shutdown was reported in a significant proportion of COVID-19 ICU patients using viscoelastic testing and this was associated with a higher incidence of thrombotic complications [74] . While the exact mechanisms for suppressed fibrinolysis in Covid-19 are uncertain, plausible mechanisms include activation of Thrombin Activable Fibrinolysis Inhibitor (TAFI) by high concentrations of thrombin due to a hypercoagulable state and increased release of PAI-1 from endothelial cells and activated platelets secondary to inflammation [73] . Another possible mechanism is overactivation of the Renin-Angiotensin system due to SARS-CoV-2 mediated downregulation of ACE2, leading to unopposed Angiotensin II effects which increases the expression of PAI-1 [75, 76] . Of note, however, significantly elevated D dimer, a breakdown product of fibrin is a common feature of late, severe disease, suggesting that the fibrinolytic system is still functional. This has led to the alternative hypothesis that "consumptive fibrinolysis", a failing attempt of the fibrinolytic system to remove fibrin and necrotic tissue from the lung parenchyma, with the fibrinolytic system being consumed or overwhelmed in the process occurs rather than "fibrinolytic shutdown" per se [77] . The same authors propose a "plasmin paradox" in which anti-fibrinolytics may be protective in the early stages of COVID-19 through an antiviral effect, whereas exogenous plasmin(ogen) or plasminogen activators may be useful in later stages to enhance fibrinolysis [77] .

COVID-19 associated coagulopathy is characterised by significantly elevated D Dimer and fibrinogen, mild thrombocytopenia and mildly prolonged prothrombin (PT) and activated partial thrombin time (APTT). This laboratory pattern is distinct from DIC/SIC and other coagulopathies [10] although progression to DIC can also occur. DIC typically occurs between 7-10 days after admission, but can occur as early as 4 days and may be due to secondary causes independent of COVID-19 effects, such as prolonged hospitalization, mechanical ventilation, superinfection, and other typical ICU aetiologies [78] . D Dimer is the most well-studied biomarker and consistent predictor of outcome in COVID-19

patients. Studies have shown that levels of D Dimer correlate with disease severity [79] and can be used to predict the risk of venous thromboembolism, [4] need for ventilatory support, [80] and mortality. [81] Interim guidelines from the International Society on Thrombosis and Haemostasis (ISTH) recommend performing D Dimer, prothrombin (PT), platelet count and fibrinogen on admission as a risk stratification tool [82] . It has also been suggested that D Dimer, PT, and platelet count should be repeated every 2-3 days to monitor for the development of coagulopathy [83] .

A high incidence of thrombotic complications occurs in COVID-19 patients with venous or arterial thrombotic complications reported in one-third of ICU patients despite pharmacological thromboprophylaxis [84] . VTE accounts for the majority of thrombotic events although arterial thrombosis such stroke and acute myocardial infarction also occurs [85] . [4] . In another meta-analysis, VTE occurred in 24% (95% PI, 5%-66%), PE in 19% (95% PI, 6%-47%), and DVT alone in 7% (95% PI, 0%-69%) of ICU patients [86] .

Taken together, this suggests a higher incidence of VTE in patients with severe COVID-19 compared to historical cohorts of ICU patients (5% to 15%) [4] . Interestingly, the prevalence of pulmonary embolism

(PE) appears to be disproportionately high relative to deep venous thrombosis (DVT) with one study reporting PE accounting for up to 80% of all thrombotic events in ICU patients [84] suggesting that the underlying mechanism is primary in-situ thrombosis (pulmonary arterial thrombosis) rather than embolism. This has led to the use of new terminology such as 'diffuse pulmonary intravascular coagulation' or 'microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome'

(MicroCLOTS) to describe this phenomenon [87, 88] . In keeping with this theory, an autopsy series of 11 patients with COVID-19 found thrombosis predominantly affecting small and mid-sized (subsegmental/segmental) pulmonary arteries [89] .

Most societal guidelines recommend thromboprophylaxis with low molecular weight heparin (LMWH) or unfractionated heparin (UFH) in all hospitalised patients unless contraindicated [82, [90] [91] [92] .

However, there is no consensus regarding the optimal risk stratification, intensity and duration of anticoagulation or whether post-hospital discharge should be given [93] . Another concern is the need for monitoring with warfarin and unfractionated heparin which may J o u r n a l P r e -p r o o f increase health care worker exposure due to frequent blood draws. Finally, heparin resistance due to acute phase reactants may be an issue with unfractionated heparin.

The high incidence of thrombosis in COVID-19 patients despite standard prophylaxis and association of thrombosis with increased mortality [98] has led to the search for novel approaches to prevent thrombosis driven by an overactive immune response beyond traditional anticoagulation strategies alone. For example, immune modulators or immunosuppressive therapy such as hydroxychloroquine, corticosteroids and IL-6 inhibitors have been used in clinical trials to target pathways upstream of the coagulation cascade. In addition, a number of antithrombotics have been repurposed which in addition to their direct antithrombotic effects may also have other potential mechanisms of action such as antiviral or anti-inflammatory effects. An extensive discussion of potential pharmacological agents targeting immunothrombosis is beyond the scope of this review and for this the reader is referred to a recent review article prepared by the Global COVID-19 Thrombosis Collaborative Group [99] . However, a few selected candidate therapies are briefly discussed here. In addition, table 1 gives a summary of a number of clinical trials investigating the use of these potential therapeutic agents in COVID-19 associated immunothrombosis.

Nebulised heparin has been proposed as one of the potential therapeutic agents for COVID-19 induced ARDS and pneumonia. Besides its anticoagulant properties, unfractionated heparin may also have other advantages through off-target effects. Heparan sulphate is used as a co-receptor for some coronaviruses (including SARS-COV-2) for host cell attachment. Nebulised heparin may thus have an anti-viral effect by competitive binding to the SAR-COV-2 surface protein S1 thus inhibiting viral entry.

In addition, there is evidence that heparin also has anti-inflammatory and mucolytic properties. (table 1) .

Fibrinolytic therapy is another potential treatment for thrombotic complications and ARDS in COVID-19 patients. ARDS develops in about 5% of COVID-19 patients and is characterised by a diffuse inflammatory reaction, progressing through 3 phases -exudative, proliferative and fibrosis. The hallmark of ARDS is diffuse alveolar damage and fibrin deposition, leading to hyaline membrane formation and subsequent alveolar fibrosis. This, coupled with association of a hypofibrinolytic state in ARDS due to upregulation of PAI-1 has provided a rationale for the use of fibrinolytic therapy in COVID-19 patients. Indeed, use of fibrinolytics such as urokinase or tissue plasminogen activator has been shown to prevent ARDS in porcine models [101] and results of a phase 1 clinical trial to treat ARDS in critically ill patients has been promising with improvements in oxygenation [102] . To date, only a small case series for the use of fibrinolytic therapy in COVID-19 patients has been reported [103] . The main concern is the risk of bleeding, especially intracranial bleeding which is reported to occur in 1-3% of patients given systemic thrombolysis [104, 105] . In this context, viscoelastic testing may be of value to identify patients with fibrinolytic shutdown who may benefit most from fibrinolytic therapy [74] . The use of nebulised plasminogen activator to promote local fibrinolysis in the lungs while minimising the risk of systemic bleeding has also been proposed and the results of an ongoing phase 2 clinical trial using nebulised fibrinolysis in COVID-19 patients (NCT04356833) are eagerly awaited.

Dipyridamole is a phosphodiesterase inhibitor that inhibits platelet aggregation by increasing the intracellular concentration of cyclic adenosine monophosphate. Pre-clinical studies have shown that dipyridamole is able to inhibit NETosis and thrombosis in antiphospholipid syndrome by activation of adenosine A2A receptors [106] . In addition, Dipyridamole has a broad-spectrum activity to a wide range J o u r n a l P r e -p r o o f of viruses and is able to inhibit positive-stranded RNA viruses in vitro [107] . A recent study showed that dipyridamole has specific affinity to the human coronavirus (HCoV- 19) protease Mpro using in silico data and suppresses HCoV-19 replication in vitro. Further, Dipyridamole was shown to induce type 1 interferon response and prolong survival in a mouse model of viral pneumonia. The study also provided early data suggesting a clinical benefit of dipyridamole in a small group of severely ill COVID-19 patients (n =31) who were treated with concomitant antiviral drugs. Compared to controls, patients treated with Dipyridamole had decreased D-dimer levels, improvements in platelet and lymphocyte counts and a trend towards improved clinical outcomes including clinical cure and discharge rates [108] . While this data is encouraging, further high-quality studies are needed for confirmation.

A potential role for complement inhibition in COVID-19 is supported by studies showing efficacy of this approach in murine models of SARS-CoV [49] and MERSCoV [57] , as well as autopsy evidence of complement deposition in organs of patients with severe COVID-19 [56] . Eculizumab, a C5 inhibitor has already been used successfully in the treatment of atypical haemolytic uraemic syndrome, a complement mediated disease. The use of eculizumab [109] and IFX-1, another anti-C5a monoclonal antibody [110] has recently been reported in a small number of patients with COVID-19 although further studies are currently underway. Another promising target is C3 which is positioned at the convergence of all three activation pathways, upstream of C5. Inhibition of C3 simultaneously blocks both C3a and C5a thus leading to more potent inhibition of the complement cascade. In addition, inhibition of C3 can also prevent IL-6 release from cells such as macrophages expressing the C3aR [111] . One such drug compound is Compstatin (AMY-101), a C3 inhibitor which is currently undergoing investigation in phase 2 clinical trials of COVID-19 patients with ARDS (NCT04395456). A third potential target is the lectin pathway. MASP-2 an activator of the lectin pathway has been shown to bind to the nucleocapsid protein of coronaviruses such as MERSCoV, SARS-CoV, and SARS-CoV2 [112] .

Suppression of this pathway can be achieved using the anti-MASP2 antibody narsoplimab [113] .

J o u r n a l P r e -p r o o f

In summary, the coagulopathy associated with COVID-19 is the consequence of a complex interplay between the immune, endothelium and coagulation system, with bidirectional interactions, resulting in a procoagulant milieu. The observation of a high incidence of thrombotic event despite routine thromboprophylaxis suggests a different approach is required. In particular, targeting pathways upstream of coagulation using novel or repurposed drugs alone or in combination with other antithrombotic agents may be a rational approach to reduce the mortality and morbidity associated with 

The authors declare no conflict of interests.

The authors declare no conflict of interests. 

Severe Covid-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications

Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis

Infection Depends on Cellular Heparan Sulfate and ACE2

SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis

Clinical and immunological features of severe and moderate coronavirus disease 2019

Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies

The unique characteristics of COVID-19 coagulopathy

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19 and multisystem inflammatory syndrome in children and adolescents

Immune determinants of COVID-19 disease presentation and severity

Is a "cytokine Storm" Relevant to COVID-19?

Cytokine Levels in Critically Ill Patients with COVID-19 and Other Conditions

Immune pathogenesis of covid-19 intoxication: Storm or silence?

A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

Coagulopathy of Coronavirus Disease

Coagulation Abnormalities and Thrombosis in Patients Infected with SARS-CoV-2 and Other Pandemic Viruses

Thrombosis and coagulopathy in COVID-19: An illustrated review

Endothelial cell control of thrombosis

Endothelial cell infection and endotheliitis in COVID-19

Targeting the NLRP3 Inflammasome in Severe COVID-19

COVID-19 Infection: Viral Macro-and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management

Thrombosis and COVID-19 pneumonia: The clot thickens!

Endothelial cells orchestrate COVID-19 coagulopathy

COVID-19: the vasculature unleashed

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

Circulating platelets as mediators of immunity, inflammation, and thrombosis

Platelets in Coronavirus Disease

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis

Platelet gene expression and function in patients with COVID-19

Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19

Platelets Can Associate with SARS-CoV-2 RNA and Are Hyperactivated in COVID-19

Potential role of platelets in COVID-19: Implications for thrombosis

Neutrophil Extracellular Traps in Arterial and Venous Thrombosis

Neutrophils Ameliorate Lung Injury and the Development of Severe Disease during Influenza Infection

A role for neutrophils in viral respiratory disease

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Vascular occlusion by neutrophil extracellular traps in COVID-19

Neutrophil extracellular traps in COVID-19

Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy

Neutrophil extracellular traps and thrombosis in COVID-19

Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis

Cross Talk Pathways between Coagulation and Inflammation

Interaction between the coagulation and complement system

Mechanisms of activation of the classical pathway of complement by Hageman factor fragment

Kallikrein Cleaves C3 and Activates Complement

Blood platelets activate the classical pathway of human complement

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV article

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

Lupus anticoagulant is frequent in patients with Covid-19

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Antiphospholipid Antibodies in Critically Ill Patients With COVID-19

Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients

Presence of antiphospholipid antibodies in COVID-19: case series study

Anticardiolipin IgG Autoantibody Level Is an Independent Risk Factor for COVID-19 Severity

Coagulopathy of COVID-19 and antiphospholipid antibodies

Antiphospholipid antibodies in patients with COVID-19: A relevant observation?

Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: Findings from a multicentre study on 122 cases

Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19

Coagulation, fibrinolysis, and fibrin deposition in acute lung injury

Sepsis-induced Coagulopathy and Disseminated Intravascular Coagulation

Mechanisms of severe acute respiratory syndrome coronavirus-induced acute lung injury

Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis

Fibrinolysis Shutdown Correlation with Thromboembolic Events in Severe COVID-19 Infection

Coagulation dysfunction in COVID-19: The interplay between inflammation, viral infection and the coagulation system

Thrombosis in COVID-19

Fibrinolysis and COVID-19: A plasmin paradox

COVID-19 and its implications for thrombosis and anticoagulation

D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis

Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients with COVID-19

Elevated D-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: A systematic review and meta-analysis

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Coagulation abnormalities and thrombosis in patients with

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Arterial Thrombosis in Coronavirus Disease 2019 Patients: A Rapid Systematic Review

Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia

Microvascular COVID-19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis -PubMed

Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective, Single-Center

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review

Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019: CHEST Guideline and Expert Panel Report

Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19: Implications for clinical practice and future investigations

Anticoagulant interventions in hospitalized patients with COVID-19: A scoping review of randomized controlled trials and call for international collaboration

Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19

Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial

Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis, EClinicalMedicine

Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research

Nebulised heparin as a treatment for COVID-19: Scientific rationale and a call for randomised evidence

Prevention of adult respiratory distress syndrome with plasminogen activator in pigs

Treatment of severe acute respiratory distress syndrome: a final report on a phase I study -PubMed

Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series

Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage

Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)

Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome

Dipyridamole Reversibly Inhibits Mengovirus RNA Replication

Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19

Eculizumab treatment in patients with COVID-19: Preliminary results from real life ASL Napoli 2 Nord experience

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Clinical promise of next-generation complement therapeutics

Highly pathogenic coronavirus N protein injury by MASP-2-mediated complement over-activation

MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab

None